Funding for this research was provided by:
Text and Data Mining valid from 2019-09-07
Received: 30 April 2019
Accepted: 22 August 2019
First Online: 7 September 2019
Ethics approval and consent to participate
: The study protocol was approved by the Medical Ethics Committee of the Charité – Universitätsmedizin Berlin, Germany under the number EA1/219/15. A signed patient information and informed consent form was obtained from all participating patients.
: Not applicable.
: This work was supported Almirall Hermal GmbH, the manufacturer of Tetrahydrocannabinol/Cannabidiol (THC:CBD). TM and CM are founders of the internet platform Ambulanzpartner and hold shares of Ambulanzpartner Soziotechnologie APST GmbH. TM received consultancy fees from Cytokinetics, Biogen, Mitsubishi Tanabe, TEVA and Desitin Arzneimittel GmbH.